Because fulvestrant (pure estrogen receptor antagonist)-resistant breast cancer frequently shows the upregulation of mTOR pathway, the combination of fulvestrant and mTOR inhibitor is more efficious than fulvestrant alone [31]. The gene discussed is ESR1; the disease is breast carcinoma.